![]() |
市場調查報告書
商品編碼
1496772
氣喘藥物市場:依產品、藥物類別、給藥途徑- 全球預測 2024-2030Asthma Therapeutics Market by Product (Inhalers, Nebulizers), Drug Class (Anti-Inflammatory, Bronchodilators, Combination Therapy), Route of administration - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年氣喘治療市場規模為247億美元,預計2024年將達272.6億美元,2030年將達501億美元,複合年成長率為10.63%。
氣喘治療市場包括與治療和緩解氣喘(一種慢性呼吸道疾病)症狀的藥物和治療方法的研究、開發、生產和分銷相關的所有活動。該市場服務於不同年齡層的不同患者群體,他們需要對氣喘發作進行維持或急性治療。市場範圍包括多種治療藥物,如發炎藥物、支氣管擴張劑、聯合治療、生物製藥以及吸入器和霧化器等輸送裝置。氣喘藥物市場的主要應用包括旨在維持病情穩定的長期治療藥物,以及針對急性症狀的即時治療藥物。這些產品的最終用戶通常是被診斷患有氣喘的個人、肺科醫生等醫療保健專業人員以及醫院、診所和居家照護機構等醫療保健機構。這也延伸到支援服務,例如病患教育和正確使用氣喘管理設備的培訓。由於氣喘和其他呼吸系統疾病盛行率的增加、過敏檢測和診斷技術的最新改進以及對單株抗體的廣泛需求,對氣喘治療藥物的需求正在增加。然而,氣喘治療市場面臨著諸如氣喘治療設備的局限性和副作用、先進治療的高成本以及偏遠和農村地區的治療覆蓋範圍有限等挑戰。同時,氣喘治療市場正在出現一些商機,包括治療聯合治療市場的開拓以及氣喘治療的廣泛研發(R&D)。數位健康解決方案的趨勢也在不斷成長,例如可以追蹤使用情況並提醒患者服藥的智慧吸入器,從而為與科技和製藥公司的合作提供了機會。
主要市場統計 | |
---|---|
基準年[2023] | 247億美元 |
預測年份 [2024] | 272.6億美元 |
預測年份 [2030] | 501億美元 |
複合年成長率(%) | 10.63% |
區域洞察
美國氣喘藥物市場是由氣喘高盛行率和強大的醫療基礎設施所推動的。專利到期、新型生技藥品和個人化醫療正在推動該地區的研究和創新。該地區的各個組織不斷發現治療方法並控制氣喘、食物過敏、鼻過敏和其他過敏性疾病。南美洲對氣喘治療藥物的需求正在增加,這主要是由於人們對呼吸系統疾病的認知提高和醫療設施的改善。歐洲是氣喘藥物的重要市場,並得到高認知、完善的醫療保健系統和有利的報銷政策的支持。幾個主要市場參與企業的存在以及對研發活動的重視也是值得注意的因素。德國、法國、瑞士、英國、法國和義大利等西歐國家佔據主要市場佔有率,而東歐國家則因醫療基礎設施改善和氣喘盛行率上升而顯示出成長潛力。由於醫療基礎設施的改善和私營部門投資的增加,中東市場正在不斷發展。同時,非洲面臨醫療服務有限、認知度低、獲得治療機會不足等挑戰,阻礙了市場成長。然而,南非等某些國家在氣喘治療方面正在取得進展,這可能會對區域市場的開拓產生正面影響。在亞太地區,由於中階的不斷壯大和醫療改革的加強,中國的氣喘治療市場正在快速發展。在日本,患者可以獲得一些最先進的治療方法,反映出先進的醫療保健系統和患者的高度意識。日本的製藥業具有高度創新性,擁有強大的新藥研發管線以及持續的研發投資。印度氣喘治療市場的特點是需要負擔得起的藥物和加強氣喘管理教育。由於人口眾多和污染問題,氣喘的盛行率正在增加。政府計畫和非營利舉措旨在提高整個次大陸氣喘治療的可近性和可負擔性。
FPNV定位矩陣
FPNV 定位矩陣對於評估氣喘治療藥物市場供應商的市場定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對氣喘治療市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭性質的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對公司目前在氣喘藥物市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[195 Pages Report] The Asthma Therapeutics Market size was estimated at USD 24.70 billion in 2023 and expected to reach USD 27.26 billion in 2024, at a CAGR 10.63% to reach USD 50.10 billion by 2030.
The asthma therapeutics market encompasses all activities related to the research, development, production, and distribution of medications and treatments designed to manage and alleviate the symptoms of asthma, a chronic respiratory disorder. This market serves a diverse population of patients across age groups who require either maintenance therapy or acute care for asthmatic episodes. The market scope includes various therapeutic products such as anti-inflammatory drugs, bronchodilators, combination therapies, biologics, and delivery devices such as inhalers and nebulizers. The primary applications within the asthma therapeutics market include long-term control medicines, which aim to maintain a stable condition, and quick-relief treatments for sudden symptoms. End-users of these products typically entail individuals diagnosed with asthma, healthcare professionals like pulmonologists, and healthcare settings, including hospitals, clinics, and homecare environments. The scope extends to support services like patient education and training on the proper use of asthma management devices. The need for asthma therapeutics is increasing due to growing incidences of asthma and other respiratory diseases, recent improvements in allergy detection and diagnostic technologies, and extensive demand for monoclonal antibodies. However, the asthma therapeutics market faces certain challenges, including limitations and side effects of asthma therapeutic devices, high costs associated with advanced treatments, and limited therapeutic reach in remote and rural areas. On the other hand, several opportunities are emerging within the asthma therapeutics market, including the development of combination therapeutics for the treatment and extensive research and development (R&D) efforts for asthma treatment. There is also an increasing trend towards digital health solutions, such as smart inhalers that can track usage and remind patients about doses, opening opportunities for tech companies and pharmaceutical partnerships.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 24.70 billion |
Estimated Year [2024] | USD 27.26 billion |
Forecast Year [2030] | USD 50.10 billion |
CAGR (%) | 10.63% |
Regional Insights
In the United States, the asthma therapeutics market is driven by a high prevalence of asthma alongside strong healthcare infrastructure. Patent expirations, novel biologics, and personalized medicine drive research and innovation in the region. Various organizations in the region continue to find a cure for and control asthma, food allergies, nasal allergies, and other allergic diseases. South America shows a growing need for asthma therapeutics, largely due to increasing awareness of respiratory diseases and improving healthcare facilities. Europe represents a substantial market for asthma therapeutics, supported by high awareness levels, established healthcare systems, and favorable reimbursement policies. The presence of several key market players and a strong emphasis on research and development activities are notable factors. Western European countries, including Germany, France, Switzerland, the United Kingdom, France, and Italy, hold a major market share, while Eastern European countries exhibit potential for growth due to improving healthcare infrastructure and rising asthma prevalence. The market in the Middle East is advancing with the development of healthcare infrastructure and increasing private sector investment. In contrast, Africa faces challenges such as limited healthcare services, low awareness, and inadequate access to treatment, which hinder market growth. However, certain countries, including South Africa, are making strides in asthma care, which can positively influence regional market development. In APAC, China's asthma therapeutic market is developing rapidly due to the growing middle class and enhanced healthcare reforms. In Japan, patients have access to several state-of-the-art treatments, reflecting the country's advanced healthcare system and high patient awareness. Japan's pharmaceutical sector is highly innovative, with a robust pipeline of new drugs and consistent investment in R&D. India's asthma treatment market is characterized by a need for affordable medications and increased education on asthma management. The high population, coupled with pollution issues, contributes to a growing prevalence of asthma. Government programs and non-profit initiatives aim to enhance asthma care accessibility and affordability throughout the subcontinent.
Market Insights
The market dynamics represent an ever-changing landscape of the Asthma Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Asthma Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Asthma Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
GSK Boosts Respiratory Portfolio with $1.4 Billion Aiolos Bio Acquisition
GlaxoSmithKline PLC has announced the acquisition of Aiolos Bio Inc. with an investment of USD 1.4 billion. This acquisition aims to enhance GSK's foothold in the asthma treatment market as this deal gives GSK access to AIO-001, a cutting-edge asthma therapy by Aiolos Bio. [Published On: 2024-01-09]
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
Teva Pharmaceutical Industries Ltd. and Biolojic Design Ltd. announced an exclusive license agreement to develop a potential novel antibody-based therapy for treating Atopic Dermatitis and Asthma. BD9 is novel for its dual-action mechanism that inhibits both TSLP and IL-13, offering a more comprehensive treatment option over current single-target therapies. This collaboration is a strategic move complementing Teva's 'Pivot to Growth' strategy, which was unveiled in May 2023 and focuses on stoking innovation through partnerships and enhancing Teva's early-stage pipeline. [Published On: 2023-12-14]
Lupin Launches Luforbec(R) 100/6 for Adult Asthma and COPD Treatment
Hormosan Pharma GmbH, a fully owned subsidiary of Lupin Limited, announced the launch of Luforbec 100/6, a fixed blend in a pressurized metered dose inhaler (pMDI) for the remedy of adult chronic obstructive pulmonary disease (COPD) and asthma in Germany. [Published On: 2023-09-26]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Asthma Therapeutics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Asthma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Biogen Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Chiesi Farmaceutici S.p.A., Cipla Limited, F. Hoffmann-La Roche Ltd, Genentech, Inc., GlaxoSmithKline PLC, Kare Medical and Analytical Devices Ltd. Co., Koninklijke Philips N.V., Lupin Limited, Medtronic PLC, Merck & Co, Inc., Merxin Ltd., Novartis AG, Parekhplast India Limited, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Shenzhen Aeon Technology Co., Ltd., Softhale NV by invoX Pharma Limited, Sun Pharmaceutical Industries Limited, Sunovion Pharmaceuticals, Inc., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., Trudell Medical Limited, Viatris Inc., and Wellinks, Inc..
Market Segmentation & Coverage